Teva Pharmaceutical Industries Ltd (TEVA)

pos +0.16
Today's Range: 43.29 - 43.44 | TEVA Avg Daily Volume: 6,565,500
Last Update: 10/25/16 - 9:54 AM EDT
Volume: 459,452
YTD Performance: -33.73%
Open: $43.34
Previous Close: $43.50
52 Week Range: $41.67 - $66.55
Oustanding Shares: 914,000,000
Market Cap: 40,216,000,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 10 9 12
Moderate Buy 2 2 2 2
Hold 5 4 5 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.68 1.59 1.72 1.53
Latest Dividend: 0.29
Latest Dividend Yield: 2.63%
Dividend Ex-Date: 08/18/16
Price Earnings Ratio: 24.18
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
24.18 22.90 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-20.52% -26.95% 7.89%
Revenue -3.10 0.00 -0.01
Net Income -47.50 -0.20 -0.06
EPS -48.90 -0.20 -0.06
Earnings for TEVA:
Revenue 19.65B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $1.27 $1.41 $5.17 $5.91
Number of Analysts 4 4 7 7
High Estimate $1.31 $1.43 $5.28 $6.18
Low Estimate $1.24 $1.41 $5.06 $5.25
Prior Year $1.35 $1.28 $5.42 $5.17
Growth Rate (Year over Year) -5.56% 10.55% -4.67% 14.38%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
The likely continuation of a split government should help the sector recover from its recent beat-down.
Oct 07, 2016 | 7:28 AM EDT
Shares of TEVA now seen reaching $57, according to Leerink Partners. Estimates also reduced, given near-term headwinds Outperform ratin...
Problems have hit some favorite names, but opportunities are becoming apparent.
Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.
There are no bullish divergences of consequence to suggest that the stock might be poised to rally.
These stocks look good as seasonal volatility sets in.
Without it, the uncertainty would be incredible between now and November.
The EpiPen controversy makes this stock a shot in the dark.
Here are three recent examples of how the patient can profit.
The leadership is quite stark.

Columnist Conversations

General Motors is moving well today.  The stock is up just over 2.5% with the help of  nice bump in ...
with earnings this week, we will take this winner off and roll up. SOLD GOOGL NOV 825 CALL AT ...
we'll add some of these here as the technicals are favorable BOUGHT DIS JAN 95 CALL AT 2.15 ...
Market is off to a good start to begin the trading week.  Equities up nicely across the board.  Oil ...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.